Energy & Endurance
AOD-9604
← Back to Library
Limited / unverified FDA safety flag Limited / unverified Metabolic Aesthetics
Educational reference only. Read the full disclaimer.
The protocols below are not automatically an FDA-approved or clinically verified regimen unless
explicitly marked as label-verified or clinical-trial above.
Overview
Route(s): Subcutaneous
Typical vial sizes: 2, 5 mg
Dosing window: Morning Fasted
Receptor / target: HGH Lipolytic Fragment (177-191)
Properties: Half-life: ~3 hours
Pre-mixed: No
Unverified protocol notes
Standard Protocol
| Timeframe | Dose | Notes |
|---|---|---|
| Weeks 1-4 | 300 mcg 1x Daily Fasted | AM upon waking preferred, do not eat 2-4 hrs post pinning. |
| Weeks 5-12 | 500 mcg 1x Daily Fasted | AM upon waking preferred, do not eat 2-4 hrs post pinning. |
Unverified protocol note; not label dosing unless graded otherwise on this page.
Alternative Titration 1
| Timeframe | Dose | Notes |
|---|---|---|
| Weeks 1-3 | 300 mcg 1x Daily Fasted | AM upon waking preferred, do not eat 2-4 hrs post pinning. |
Unverified alternative protocol; not an approved-label regimen unless graded otherwise on this page.
Alternative Titration 2: Weight Loss Protocol
| Timeframe | Dose | Notes |
|---|---|---|
| Weeks 1-3 | 250mcg 2x Daily Fasted | AM upon waking and PM 1hr post meal, do not eat 2-4 hrs post pinning. |
Unverified alternative protocol; not an approved-label regimen unless graded otherwise on this page.
Protocol logic check
Protocol context: Energy protocols are usually about mitochondrial or metabolic signaling. The logic is timing around meals/training, avoiding late-day stimulation, and watching sleep, glucose, blood pressure, and overtraining signals. Entry context: target (HGH Lipolytic Fragment (177-191)); route Subcutaneous; timing Morning Fasted. Limited-evidence dosing tables are hypotheses, not recommendations. FDA/safety flags lower confidence and raise the evidence bar for any claimed benefit. Compatibility is conditional: a reasonable solo compound can become inappropriate once a contraindicated partner is added. AOD-9604 is often sold with spot-fat-loss language, but the dosing logic should stay systemic and evidence-cautious. Local injection claims do not prove local fat loss, and appetite, diet adherence, and total energy balance still decide visible change.
Independent evidence
Independent safety notes: FDA lists AOD-9604 among withdrawn nominated bulk substances with potential significant safety risks and limited safety information.
Regulatory status: unapproved or compounded peptide with FDA safety risk flag
Storage
No independently verified storage guidance found. Treat any unverified storage claim as unverified, and see the general storage guidance in the FAQ.
Contraindications (limited evidence)
- Active cancer or history of growth hormone-sensitive tumors: although AOD-9604 does not significantly elevate IGF-1, any compound acting on GH-adjacent pathways warrants caution in oncology contexts. Limited / unverified
- Concurrent use with Adipotide: both compounds target adipose tissue through distinct destructive or disruptive mechanisms; combined use creates unpredictable and potentially dangerous systemic fat cell stress. Limited / unverified
- Concurrent use with AOD-CJC-IPA blend: results in double-dosing of AOD-9604 within the same protocol. Limited / unverified
- Pregnancy: safety not established; potential fetal risk. Limited / unverified
- Breastfeeding: safety not established. Limited / unverified
- Known hypersensitivity or anaphylaxis to AOD-9604 or formulation excipients. Limited / unverified
- Severe hepatic impairment: limited metabolic clearance data. Limited / unverified
- Severe renal impairment: limited clearance data; dehydration risk. Limited / unverified
- Endocrine disorders involving active GH excess (e.g., acromegaly): additive lipolytic GH pathway stimulation. Limited / unverified
- Diabetes mellitus requiring tight glycemic management: while AOD-9604 does not directly alter glucose, rapid systemic lipolysis releases free fatty acids that may transiently affect insulin sensitivity in brittle diabetics. Limited / unverified
Side effects (limited evidence)
- Injection site reactions: redness, swelling, and irritation at the administration site; reported in approximately 12.8% of subjects in Phase 2 data. Limited / unverified
- Nausea: reported in approximately 8.4% of subjects; typically mild and transient. Limited / unverified
- Headache: reported in approximately 6.7% of subjects; often dose-related and more common at the 500mcg dose. Limited / unverified
- Fatigue or lethargy during the adaptation period: reported in approximately 5.3% of subjects. Limited / unverified
- Dizziness: reported in approximately 3.8% of subjects. Limited / unverified
- Flushing: transient warmth or redness, particularly following injection; attributed to beta-3 adrenergic activation. Limited / unverified
- Transient changes in appetite: increased or decreased hunger during early protocol stages; inconsistent across subjects. Limited / unverified
- Gelation-related injection issues: failure to reconstitute with acetic acid/bacteriostatic water blend results in a gelled, ineffective solution that causes unnecessary injection site irritation. Limited / unverified
- Blunted efficacy from feeding: eating within 2 hours post-injection significantly reduces lipolytic effect; not a side effect per se but a primary protocol compliance risk. Limited / unverified
- Allergic reactions: rare; localized rash or itching at injection site. Limited / unverified
Compatibility
The relationships below come from the source site's internal engine and were not verified independently. Treat them as a starting point for a conversation with a clinician. They carry no safety guarantee.
Reported synergistic:
Reported contraindicated combinations:
Adipotide (FTPP)aod-cjc-ipa-blend